Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Apogee Therapeutics Inc. (APGE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HBK Investments David Costen Haley | 2,850,000 | $378,280,500 | 3.7% | |
| 2. | Driehaus Capital Richard Driehaus | 1,740,101 | $230,963,606 | -10% | 1.34% |
| 3. | Balyasny Asset Management Dmitry Balyasny | 1,665,102 | $221,008,988 | +280% | 0.28% |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 1,576,385 | $209,233,581 | +17% | 3.92% |
| 5. | Millennium Management Israel Englander | 1,491,404 | $197,954,053 | +1511% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.85 | 12,500 | $623,125.00 | 20,000 | 2024-12-12 | Filing | |
| $49.02 | 7,500 | $367,650.00 | 7,500 | 2024-12-12 | Filing | |
| $17.00 | 1,750,000 | $29,750,000.00 | 1,750,000 | 2023-07-13 | Filing | |
| $17.00 | 892,529 | $15,172,993.00 | 892,529 | 2023-07-13 | Filing | |
| $17.00 | 1,992,734 | $33,876,478.00 | 1,992,734 | 2023-07-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.17 | 5,500 | $737,935.00 | 168,498 | 2026-08-05 | Filing | |
| $133.63 | 20,000 | $2,672,600.00 | 995,987 | 2026-07-08 | Filing | |
| $132.74 | 5,500 | $730,070.00 | 177,873 | 2026-07-01 | Filing | |
| $132.60 | 26,400 | $3,500,640.00 | 179,248 | 2026-06-22 | Filing | |
| $132.54 | 80,000 | $10,603,200.00 | 1,015,987 | 2026-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,493,321 | $1,127,318,496 | 34.18% | |
| 2. | 5,507,032 | $730,948,292 | 0.01% | |
| 3. | 2,572,119 | $341,397,355 | 0.01% | |
| 4. | 2,493,137 | $330,914,038 | 0.01% | |
| 5. | 2,297,743 | $304,979,428 | 0.01% |
News See All
3 Best ETFs With 50%+ Upside to Buy in August 2026, According to Analysts
Analysts see a few thematic ETFs that stand out this August for investors seeking long‑run growth in digital assets and healthcare. These include t...
10 Stocks Paying Off Big Time
Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks.
12 Best High Short Interest Stocks With Highest Upside Potential
In this article, we will discuss the 12 Best High Short Interest Stocks With Highest Upside Potential.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
Wedbush Raises Price Target on Apogee Therapeutics (APGE)
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 3, Wedbush increased its price target on Apogee Therapeutics Inc.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc.
13 Hot Stocks to Buy with the Highest Upside Potential
In this article, we talk about the 13 hot stocks to buy with the highest upside potential.
Here is Why Apogee Therapeutics (APGE) Appears Attractive
Apogee Therapeutics (NASDAQ:APGE) is one of the 17 biotechnology stocks with more than 50% upside.
Hedge Fund Resource Center